Compare · BCAB vs GILD
BCAB vs GILD
Side-by-side comparison of BioAtla Inc. (BCAB) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCAB and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 67503.7x BCAB ($2.9M).
- Over the past year, BCAB is down 94.3% and GILD is up 26.9% - GILD leads by 121.1 points.
- GILD has been more active in the news (5 items in the past 4 weeks vs 1 for BCAB).
- GILD has more recent analyst coverage (25 ratings vs 8 for BCAB).
- Company
- BioAtla Inc.
- Gilead Sciences Inc.
- Price
- $1.79-42.35%
- $156.22-0.76%
- Market cap
- $2.9M
- $195.13B
- 1M return
- +0.00%
- +3.48%
- 1Y return
- -94.26%
- +26.88%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 1992
- News (4w)
- 1
- 5
- Recent ratings
- 8
- 25
BioAtla Inc.
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest BCAB
- BioAtla Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Medical Officer Sievers Eric covered exercise/tax liability with 134 shares, decreasing direct ownership by 1% to 11,346 units (SEC Form 4)
- Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 259 shares, decreasing direct ownership by 0.50% to 52,035 units (SEC Form 4)
- Chief Financial Officer Vasquez Christian covered exercise/tax liability with 71 shares, decreasing direct ownership by 0.67% to 10,476 units (SEC Form 4)
- BioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 10-Q filed by BioAtla Inc.
- BioAtla Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Financial Officer Vasquez Christian covered exercise/tax liability with 257 shares, decreasing direct ownership by 2% to 10,347 units (SEC Form 4)
- Chief Executive Officer Short Jay M Phd covered exercise/tax liability with 898 shares, decreasing direct ownership by 2% to 52,294 units (SEC Form 4)
- Chief Medical Officer Sievers Eric covered exercise/tax liability with 494 shares, decreasing direct ownership by 1% to 11,840 units (SEC Form 4)
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)